Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06675539 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Validation of the French Version of the Prediction of the Alcohol Withdrawal Severity Scale (PAWSS)

Study acronym: PAWSS-VF
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Nov 2024 to Nov 11, 2024
    • Site details revised
    v3
  2. Minor Re-verified, no change to tracked fieldsv2
  3. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this observational study is to validate the French version of the PAWSS scale in a population of patients with Alcohol Use Disorders. Prediction of Alcohol Withdrawal Severity Scale (PAWSS) has an excellent psychometric characteristics and predictive value of complicated alcohol withdrawal. The main question it aims to answer is: Are the psychometric properties of the French version of the PAWSS scale comparable to those of the English version in a population of alcohol use disorders subjects? AUDs participants are included and followed for three days during their hospitalization, They will performed several scales and surveys (DSM-5 AUD criteria, AUDIT, French version of PAWSS and CIWA-AR).
Trial Details
NCT Number NCT06675539
Lead Sponsor Etablissement Public de Santé Barthélemy Durand
Conditions
(from sponsor)
Addiction, Substance, Alcohol Use Disorder, Alcohol Dependence, Alcohol Withdrawal
Related terms Alcoholism, Substance Withdrawal Syndrome, Substance-Related Disorders
Enrollment 545 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov